FA

Faes Farma SAMAD Faes Stock Report

Last reporting period 30 Jun, 2024

Updated 21 Oct, 2024

Last price

Market cap $B

1.269

Small

Exchange

XMAD - Bolsa de Madrid

FAE.MC Stock Analysis

FA

Avoid

Based on Eyestock quantitative analysis, FAE.MC`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

97/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-9.7 %

Greatly overvalued

Market cap $B

1.269

Dividend yield

4.33 %

Shares outstanding

306.24 B

Faes Farma SA operates as a pharmaceutical company. The company is headquartered in Madrid, Madrid and currently employs 1,766 full-time employees. The firm specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The firm operates in Spain, Portugal, Chile and Mexico, among others. The company controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.

View Section: Eyestock Rating